The present invention provides a salt of an acidic drug and a hydrophobic cation, pharmaceutical compositions comprising such salts and methods of using such salts to treat or prevent a disease or disorder.

A compound represented by specific chemical formula, a core including the same, and core-shell dye including a shell surrounding the core, a photosensitive resin composition including the same, and a color filter manufactured using the photosensitive resin composition are disclosed.

A compound represented by specific chemical formula, a core including the same, and core-shell dye including a shell surrounding the core, a photosensitive resin composition including the same, and a color filter manufactured using the photosensitive resin composition are disclosed.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.

##STR00001##

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.

##STR00001##

A compound represented by the following general formula (I): ##STR00001##
(the symbols in the general formula (I) are as described in the Description), wherein the compound contains one or more structures selected from the following (i) and (ii): (i) A is an aliphatic hydrocarbon group containing two or more alicyclic hydrocarbon groups, containing a saturated aliphatic hydrocarbon group at a terminal position directly bound to N, and optionally containing O, S, N in a carbon chain (ii) at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a cycloalkyl group optionally containing a substituent group or an aryl group optionally containing a substituent group.

A compound represented by the following general formula (I): ##STR00001##
(the symbols in the general formula (I) are as described in the Description), wherein the compound contains one or more structures selected from the following (i) and (ii): (i) A is an aliphatic hydrocarbon group containing two or more alicyclic hydrocarbon groups, containing a saturated aliphatic hydrocarbon group at a terminal position directly bound to N, and optionally containing O, S, N in a carbon chain (ii) at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a cycloalkyl group optionally containing a substituent group or an aryl group optionally containing a substituent group.

The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of formula: ##STR00001##

The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of formula: ##STR00001##

New photoresist compositions are provided that comprise a component that comprises a radiation-insensitive ionic compound. Preferred photoresists of the invention may comprise a resin with photoacid-labile groups; a photoacid generator compound; and a radiation-insensitive ionic compound that can function to decrease undesired photogenerated-acid diffusion out of unexposed regions of a photoresist coating layer.